NTLA

Intellia Therapeutics Inc

13.51

Aug 25 • 3:59 PM ET +0.95 (7.56%)

13.57

Aftermarket • 7:49 PM ET +0.06 (0.44%)

Healthcare Biotechnology USA Small NASD

Peers: BEAM CRSP EDIT SNDX VIR BMRN IONS ALNY INCY VRTX

| Held by: ARKE ARKK XBI VTI IWM ARKG VB VBK VXF IWN

Index	RUT
Market Cap	1.89B
Enterprise Value	1.53B
Income	-399.98M
Sales	59.51M
Book/sh	5.20
Cash/sh	3.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	377
IPO	May 06, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	31.81
P/B	2.60
P/C	4.32
P/FCF	-
EV/EBITDA	-
EV/Sales	25.69
Quick Ratio	6.65
Current Ratio	6.65
Debt/Eq	0.10
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-3.36
EPS next Y	-2.67
EPS next Q	-0.80
EPS this Y	15.58%
EPS next Y	17.12%
EPS next 5Y	24.04%
EPS past 3/5Y	14.82% -9.70%
Sales past 3/5Y	9.09% 3.13%
EPS Y/Y TTM	28.42%
Sales Y/Y TTM	12.58%
EPS Q/Q	18.15%
Sales Q/Q	-46.23%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-0.09% -40.99%

Insider Own	4.41%
Insider Trans	-0.64%
Inst Own	99.54%
Inst Trans	28.49%
ROA	-45.55%
ROE	-55.44%
ROIC	-51.43%
Gross Margin	74.37%
Oper. Margin	-711.66%
Profit Margin	-672.16%
SMA20	14.01%
SMA50	1.40%
SMA200	8.76%
Trades

Shs Outstand	140.02M
Shs Float	133.94M
Short Float	33.51%
Short Ratio	9.09
Short Interest	44.88M
52W High	28.25 -52.18%
52W Low	7.95 69.94%
Volatility	6.63% 5.33%
ATR (14)	0.78
RSI (14)	59.34
Beta	1.81
Rel Volume	0.83
Avg Volume	4.94M
Volume	4,091,924

Perf Week	16.47%
Perf Month	26.62%
Perf Quarter	7.14%
Perf Half Y	-0.52%
Perf YTD	50.28%
Perf Year	18.72%
Perf 3Y	-64.68%
Perf 5Y	-91.47%
Perf 10Y	-36.15%
Recom	2.26
Target Price	23.75
Prev Close	12.56
Price	13.51
Change %	7.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-26	Downgrade	Wolfe Research	Peer Perform → Underperform	$9
Mar-02-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight	$5
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$14
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$33
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57

Show Previous Ratings

Aug-12-26 03:30PM	These Are the Stocks Wall Street Is Betting Against the Most (GuruFocus.com)
Aug-07-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
08:30AM	Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-06-26 03:03PM	Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... (GuruFocus.com)
07:00AM	Loading…
07:00AM	Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Jul-30-26 08:00AM	Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Jul-06-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-15-26 04:10AM	Why Is NTLA Stock Jumping 5% Premarket Today? (Stocktwits) +23.20%
Jun-13-26 07:30AM	Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire)
Jun-05-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Jun-01-26 07:30AM	Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 (GlobeNewswire)
May-11-26 07:30AM	Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-05-26 07:30AM	Intellia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-04-26 01:21PM	Cathie Wood Dumps $72 Million of AMD, Doubles Down on Alphabet and Meta (GuruFocus.com)
04:01PM	Loading…
May-01-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-26 08:39AM	Cathie Wood Buys Tumbling Robinhood Stock, ARK Adds $30 Mil Of This Stock (Investor's Business Daily) +8.32%
Apr-29-26 09:50AM	Cathie Wood Loads Up $14 Million on Alphabet Just Before Earnings (GuruFocus.com) -5.72%
07:00AM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
Apr-27-26 04:01PM	Intellia Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:43PM	Intellia Stock Jumps 25%. A Key Trial Is Driving the Rally (GuruFocus.com)
11:20AM	Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data (InvestorsHub)
11:07AM	This Biotech Just Lodged A First In Gene Editing; Why Analysts Are Split (Investor's Business Daily)
11:02AM	Intellia seeks FDA approval for in vivo CRISPR therapy (Quartz)
09:39AM	Intellia Stock Up on Gene-Editing Drug Success (The Wall Street Journal)
07:00AM	Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing (GlobeNewswire)
07:00AM	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema (GlobeNewswire)
04:48AM	Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder (BioPharma Dive)
Apr-24-26 04:05PM	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 (GlobeNewswire) -14.11%
Apr-03-26 04:05PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:00AM	Loading…
Mar-09-26 09:00AM	Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus (Zacks)
Mar-06-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 09:39AM	Roblox initiated, Target upgraded: Wall Street's top analyst calls (The Fly)
Mar-03-26 07:49PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -11.88%
09:00AM	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone (PR Newswire)
07:30AM	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 (GlobeNewswire)
Mar-02-26 06:44PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +12.05%
10:05AM	Intellia Therapeutics Stock Gains - FDA Lifts Clinical Hold On Pivotal Trial (Benzinga)
07:30AM	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM (GlobeNewswire)
Feb-28-26 10:07AM	Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory (Insider Monkey)
02:21AM	Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results (Insider Monkey)
Feb-27-26 11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
12:07AM	Intellia Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:34PM	Intellia Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +6.41%
04:14PM	Intellia Therapeutics Inc (NTLA) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
12:15PM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-24-26 08:00AM	Intellia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-26 10:35AM	ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks)
08:04AM	Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus (Zacks)
Feb-19-26 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
Feb-15-26 08:41AM	H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted (Insider Monkey)
Feb-09-26 08:02AM	Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus (Zacks)
Feb-06-26 07:30AM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.73%
Feb-04-26 07:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -5.29% -10.28%
Feb-02-26 09:37AM	Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal (Insider Monkey)
08:25AM	Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -6.81%
07:35AM	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
06:33AM	Intellia Therapeutics to resume dosing of gene therapy in Phase III trial (Clinical Trials Arena)
Jan-27-26 04:04PM	The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up (Investor's Business Daily) +6.31%
01:03PM	Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder (Benzinga)
08:31AM	Intellia gets FDA nod to resume gene therapy trial after safety pause (Reuters)
08:00AM	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN (GlobeNewswire)
06:59AM	FDA lifts hold on an Intellia CRISPR drug trial (BioPharma Dive)
Jan-22-26 08:47PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.33% -7.99%
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-15-26 10:56AM	JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death (Clinical Trials Arena)
Jan-14-26 09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average (Zacks)
Jan-07-26 07:30AM	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
Jan-02-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 01:33PM	Cathie Wood shells out $1.3 million on biotech stock (TheStreet)
09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 07:35AM	What Makes Intellia Therapeutics (NTLA) an Interesting Investment? (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-25 01:41PM	Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory (Insider Monkey) +7.51%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks) +5.52%
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-25-25 08:39AM	Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress (Insider Monkey)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
04:45AM	Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data (Insider Monkey)
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:00AM	Should You Buy the Dip in Intellia Therapeutics Stock? (Barchart) -8.64%
Nov-12-25 09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly) -6.78%
Nov-11-25 07:30AM	Is This Beaten-Down Cathie Wood Stock Still a Buy? (Barchart)
Nov-10-25 03:17PM	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
01:19PM	Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged (Investor's Business Daily)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
05:13PM	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.73%
04:14PM	Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies (Investor's Business Daily)

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

PresidentDr. John M. Leonard M.D.

Executive VPMr. Edward J. Dulac III

Executive VP & Chief Scientific OfficerDr. Birgit Schultes Ph.D.

J.D.Mr. James E. Basta Esq.

Co-FounderDr. Rachel E. Haurwitz Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEONARD JOHN M	President and CEO	Aug 20 '26	Sale	12.60	19,890	250,614	1,149,849	Aug 24 04:05 PM
LEONARD JOHN M	President and CEO	Aug 21 '26	Sale	13.00	2,785	36,205	1,147,064	Aug 24 04:05 PM
LEONARD JOHN M	Officer	Aug 20 '26	Proposed Sale	12.95	22,675	293,641		Aug 20 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 22 '26	Sale	11.25	8,111	91,249	148,175	Jul 24 05:26 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 01 '26	Sale	16.78	2,641	44,316	66,886	Jul 06 05:02 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 02 '26	Sale	18.00	4,677	84,186	156,286	Jul 06 05:01 PM
EDWARD DULAC	Officer	Jul 02 '26	Proposed Sale	17.24	4,677	80,631		Jul 02 04:32 PM
BASTA JAMES	EVP, General Counsel	Mar 02 '26	Sale	13.78	1,211	16,688	156,794	Mar 03 04:18 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 02 '26	Sale	13.78	607	8,364	93,864	Mar 03 04:16 PM
LEONARD JOHN M	President and CEO	Jan 05 '26	Sale	9.21	34,146	314,485	1,013,339	Jan 07 04:05 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Jan 05 '26	Sale	9.21	8,508	78,359	98,533	Jan 07 04:05 PM
BASTA JAMES	EVP, General Counsel	Jan 05 '26	Sale	9.21	10,397	95,756	101,528	Jan 07 04:05 PM
Cohen Fred E	Director	Jan 05 '26	Buy	9.35	150,000	1,402,500	207,453	Jan 07 04:05 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 05 '26	Sale	9.21	11,903	109,627	121,249	Jan 07 04:04 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 05 '26	Sale	9.21	9,515	87,633	87,118	Jan 07 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jan 05 '26	Sale	9.21	6,379	58,751	99,683	Jan 07 04:02 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 05 '26	Sale	9.21	2,989	27,529	52,277	Jan 07 04:01 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Option Exercise	6.83	49,959	341,220	1,127,074	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 12 '25	Option Exercise	6.83	8,557	58,444	1,047,485	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Sale	9.49	88,146	836,384	1,038,928	Dec 12 04:09 PM
LEONARD JOHN M	Officer	Dec 11 '25	Proposed Sale	9.33	88,146	822,402		Dec 11 04:11 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Oct 01 '25	Sale	17.38	31	539	105,184	Oct 03 05:13 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 01 '25	Sale	17.38	1,871	32,518	55,266	Oct 03 05:13 PM

Open in Screener

IQV

IQVIA Holdings Inc

259.42

Aug 25 • 3:59 PM ET -0.82 (-0.32%)

259.42

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Large NYSE

IQV IQVIA Holdings Inc daily Stock Chart

Peers: ICLR NTRA DHR LH A TMO WAT IDXX MTD BIO

| Held by: VTI VOO VO IVV SPY VTV XLV RSP VOE IWR

Index	S&P 500
Market Cap	42.70B
Enterprise Value	56.99B
Income	1.38B
Sales	16.99B
Book/sh	37.49
Cash/sh	12.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	93000
IPO	May 09, 2013

P/E	32.18
Forward P/E	17.99
PEG	1.69
P/S	2.51
P/B	6.92
P/C	20.53
P/FCF	19.55
EV/EBITDA	16.08
EV/Sales	3.36
Quick Ratio	0.71
Current Ratio	0.71
Debt/Eq	2.63
LT Debt/Eq	2.26
Option/Short	Yes / Yes

EPS (ttm)	8.06
EPS next Y	14.42
EPS next Q	3.27
EPS this Y	8.79%
EPS next Y	11.22%
EPS next 5Y	10.65%
EPS past 3/5Y	11.05% 40.52%
Sales past 3/5Y	4.18% 7.50%
EPS Y/Y TTM	16.68%
Sales Y/Y TTM	8.22%
EPS Q/Q	-0.36%
Sales Q/Q	8.84%
Earnings	Jul 28 BMO
EPS/Sales Surpr.	3.88% 1.53%

Insider Own	1.00%
Insider Trans	-6.75%
Inst Own	101.96%
Inst Trans	-1.44%
ROA	4.70%
ROE	23.01%
ROIC	6.83%
Gross Margin	26.02%
Oper. Margin	13.90%
Profit Margin	8.09%
SMA20	6.74%
SMA50	20.04%
SMA200	29.70%
Trades

Shs Outstand	164.60M
Shs Float	162.95M
Short Float	2.61%
Short Ratio	2.83
Short Interest	4.25M
52W High	261.88 -0.94%
52W Low	154.50 67.91%
Volatility	3.29% 3.38%
ATR (14)	7.94
RSI (14)	71.78
Beta	1.18
Rel Volume	0.60
Avg Volume	1.50M
Volume	901,366

Perf Week	8.08%
Perf Month	21.67%
Perf Quarter	60.14%
Perf Half Y	57.34%
Perf YTD	15.09%
Perf Year	37.97%
Perf 3Y	18.45%
Perf 5Y	0.27%
Perf 10Y	242.79%
Recom	1.50
Target Price	275.59
Prev Close	260.24
Price	259.42
Change %	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$200
Mar-09-26	Upgrade	TD Cowen	Hold → Buy	$213
Mar-06-26	Upgrade	Barclays	Equal Weight → Overweight	$210
Mar-03-26	Initiated	RBC Capital Mkts	Outperform	$221
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Nov-13-25	Initiated	BMO Capital Markets	Outperform	$260
Nov-03-25	Downgrade	TD Cowen	Buy → Hold	$215
Oct-29-25	Upgrade	Robert W. Baird	Neutral → Outperform	$258
Oct-09-25	Upgrade	HSBC Securities	Hold → Buy	$235
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$225
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Aug-24-26 02:23PM	What Is Really Moving Tempus AI Stock Right Now? (Trefis)
Aug-20-26 04:15PM	IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year (Business Wire)
Aug-17-26 04:15PM	IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group (Business Wire)
Aug-13-26 08:01AM	This Healthcare Services Stock Has 37% Upside (Barrons.com)
Aug-12-26 03:17PM	Amgen Stock And The Price Of A Promise (Trefis)
12:30PM	Loading…
Aug-06-26 12:30PM	IQVIA, Medera Partner to Accelerate Development of Cardiac Gene Therapies (Exec Edge)
Aug-04-26 04:15PM	IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery (Business Wire)
Jul-28-26 05:00PM	IQVIA Holdings Inc (IQV) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and AI-Driven ... (GuruFocus.com) +13.94%
01:49PM	IQVIA Holdings Inc. Q2 2026 Earnings Call Summary (Moby)
12:44PM	This Healthcare Stock Is Today's Best in the S&P 500 (Barrons.com)
07:14AM	IQVIA: Q2 Earnings Snapshot (Associated Press)
07:00AM	IQVIA Reports Second-Quarter 2026 Results (Business Wire)
Jul-16-26 01:39PM	IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States (Business Wire)
Jul-08-26 04:15PM	IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026 (Business Wire)
Jun-24-26 04:30PM	IQVIA Holdings Inc. stock outperforms competitors on strong trading day (MarketWatch) +8.37%
09:47AM	Loading…
Jun-17-26 09:47AM	Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls (The Fly)
09:13AM	Morgan Stanley favors Charles River Over IQVIA in CRO sector reset (Investing.com)
Jun-15-26 09:00AM	Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain (Business Wire)
Jun-04-26 10:51AM	IQVIA Announces Pricing of Senior Notes (Business Wire)
08:38AM	Is Veeva Stock Undervalued At $170? (Trefis)
Jun-03-26 02:53AM	IQVIA Announces Offering of Senior Notes (Business Wire)
May-28-26 04:30PM	IQVIA Holdings Inc. stock outperforms competitors on strong trading day (MarketWatch) +9.34%
May-26-26 04:15PM	IQVIA CEO to Speak at Jefferies Global Healthcare Conference (Business Wire)
May-13-26 04:30PM	IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities (Business Wire)
May-07-26 05:15PM	IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization (Business Wire)
May-06-26 04:15PM	IQVIA CFO to Speak at Bank of America Health Care Conference 2026 (Business Wire)
May-05-26 12:51PM	IQVIA Holdings Inc. Q1 2026 Earnings Call Summary (Moby) +9.62%
07:14AM	IQVIA: Q1 Earnings Snapshot (Associated Press)
07:00AM	IQVIA Reports First-Quarter 2026 Results (Business Wire)
Apr-24-26 11:46AM	Eli Lilly Stock Falls. Foundayo Is Fighting to Catch Novo's Wegovy Pill. (Barrons.com)
04:15PM	Loading…
Apr-15-26 04:15PM	IQVIA to Announce First-Quarter 2026 Results on May 5, 2026 (Business Wire)
04:05PM	Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown? (Barrons.com)
Mar-16-26 04:30PM	IQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences (Business Wire)
Mar-10-26 02:38PM	IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth (Insider Monkey)
10:01AM	Is IQVIA Holdings Stock Underperforming the Nasdaq? (Barchart)
Mar-09-26 09:33AM	Netflix resumed, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-04-26 10:08AM	Jim Cramer on IQVIA: "I Like the Business Very Much, I Just Don't Know Whether This Is the Right Stock to Play It" (Insider Monkey)
Mar-03-26 09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly)
Mar-02-26 04:30PM	IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference (Business Wire)
04:15PM	IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference (Business Wire)
12:13PM	Can AI Acceleration and R&D Strength Drive VEEV Ahead of Q4 Earnings? (Zacks)
Mar-01-26 04:24AM	Analysts at Mizuho Remain Bullish on IQVIA (IQV) Following Q4 Results (Insider Monkey)
Feb-27-26 04:47PM	IQVIA Releases its 2025 Sustainability Report (Business Wire)
Feb-26-26 11:53PM	Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings? (Insider Monkey) +5.39%
09:03AM	IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity (Insider Monkey)
06:42AM	IQVIA to acquire Charles River drug discovery assets (Pharmaceutical Technology)
Feb-25-26 11:08PM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
09:06AM	Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans (Benzinga)
07:00AM	IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities (Business Wire)
Feb-24-26 02:33PM	IQVIA Holdings Inc. (IQV) Offers Impressive Upside Despite AI-Linked Threats (Insider Monkey)
Feb-21-26 10:39AM	Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating (Insider Monkey)
Feb-19-26 10:36AM	TransUnion Stock Gains 6% Post Reporting Q4 Earnings & Revenue Beat (Zacks)
05:38AM	Is Wall Street Bullish or Bearish on IQVIA Holdings Stock? (Barchart)
Feb-18-26 04:15PM	IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day (Business Wire)
09:15AM	Unlocking IQVIA (IQV) International Revenues: Trends, Surprises, and Prospects (Zacks)
Feb-17-26 11:46AM	Waste Connections Stock Slides 7% Since Q4 Earnings Beat Estimates (Zacks)
Feb-13-26 08:32AM	Is the Options Market Predicting a Spike in IQVIA Stock? (Zacks)
Feb-12-26 12:30PM	Insperity Stock Price Decreases 18% After Reporting Loss in Q4 (Zacks)
12:36AM	The Top 5 Analyst Questions From IQVIA's Q4 Earnings Call (StockStory)
Feb-11-26 07:19PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Feb-10-26 08:00AM	IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions (Business Wire) -5.30%
Feb-08-26 08:39AM	Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-06-26 07:21PM	IQVIA Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
12:54AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:35AM	IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis (StockStory)
Feb-05-26 04:00PM	IQVIA Holdings Inc (IQV) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -10.65%
12:11PM	IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y (Zacks)
11:55AM	IQVIA (IQV) Stock Trades Down, Here Is Why (StockStory)
09:07AM	IQVIA backs AI strategy as analysts question impact on business (Reuters)
08:15AM	IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates (Zacks)
07:36AM	IQVIA's (NYSE:IQV) Q4 CY2025 Sales Top Estimates (StockStory)
07:20AM	IQVIA: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance (Business Wire)
Feb-04-26 11:40AM	IQV or IDXX: Which Is the Better Value Stock Right Now? (Zacks)
Feb-03-26 10:14PM	IQVIA (IQV) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory) -11.88%
11:23AM	IQVIA Set to Report Q4 Earnings: Here's What You Should Know (Zacks)
09:15AM	Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jan-29-26 08:00AM	IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration (Business Wire)
Jan-25-26 11:44AM	Beyond Biotech-3 Healthcare Stocks for Growth-Minded Investors (MarketBeat)
Jan-22-26 04:05PM	IQVIA Named to the Fortune Worlds Most Admired Companies List, Ranked No. 1 in Its Sector for Fifth Consecutive Year (Business Wire)
Jan-20-26 04:45PM	IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 (Business Wire)
Jan-15-26 09:36AM	3 Medical Device Companies in Focus for Monetizing Data and Analytics (Zacks)
Jan-14-26 09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-13-26 09:11AM	What You Need To Know Ahead of IQVIAs Earnings Release (Barchart)
Jan-12-26 11:36PM	2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down (StockStory)
Jan-11-26 11:04PM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
Jan-09-26 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
Dec-29-25 12:55PM	Here's Why You Should Retain IQV Stock in Your Portfolio Now (Zacks)
Dec-17-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-09-25 10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily)
Dec-03-25 10:32PM	Is IQVIA Holdings Stock Outperforming the S&P 500? (Barchart)
Dec-02-25 08:00AM	IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform (Business Wire)
Nov-28-25 11:30AM	Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-27-25 11:30AM	Why Is IQVIA (IQV) Up 6.4% Since Last Earnings Report? (Zacks)
Nov-26-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-11-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-06-25 10:32PM	Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission-critical information, technology solutions, and real-world evidence services to the company's life sciences clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial-related services. The Contract Sales and Medical Solutions segment offers healthcare provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1950 and is headquartered in Durham, NC.

CEO & ChairmanMr. Ari Bousbib

Executive VPMr. Eric M. Sherbet J.D.

President of Research & Development SolutionsMr. W. Richard Staub III

President of Commercial SolutionsMr. Alistair Grenfell

Executive VP & Chief Financial OfficerMr. Michael J. Fedock MBA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STAUB W RICHARD	See Remarks	Aug 03 '26	Sale	232.68	5,500	1,279,740	13,312	Aug 04 05:00 PM
Patel Bhavik	See Remarks	Jul 31 '26	Sale	235.27	1,855	436,426	1,348	Aug 04 05:00 PM
WALTER STAUB	Officer	Aug 03 '26	Proposed Sale	232.68	5,500	1,279,740		Aug 03 04:14 PM
Sherbet Eric	See Remarks	Jul 29 '26	Sale	249.16	5,000	1,245,800	20,999	Jul 31 05:04 PM
Cherofsky Keriann	See Remarks	Jul 29 '26	Sale	245.21	558	136,827	2,989	Jul 31 05:03 PM
BOUSBIB ARI	See Remarks	Jul 29 '26	Option Exercise	78.21	156,206	12,216,871	992,147	Jul 31 05:02 PM
BOUSBIB ARI	See Remarks	Jul 29 '26	Sale	245.51	106,279	26,092,072	885,868	Jul 31 05:02 PM
BHAVIK PATEL	Officer	Jul 31 '26	Proposed Sale	235.27	1,855	436,426		Jul 31 04:04 PM
KERIANN CHEROFSKY	Officer	Jul 29 '26	Proposed Sale	245.21	558	136,827		Jul 29 04:10 PM
ERIC SHERBET	Officer	Jul 29 '26	Proposed Sale	249.16	5,000	1,245,775		Jul 29 04:07 PM
ARI BOUSBIB	Officer	Jul 29 '26	Proposed Sale	245.50	106,279	26,091,897		Jul 29 04:04 PM
BOUSBIB ARI	See Remarks	Dec 18 '25	Option Exercise	59.90	50,000	2,995,000	857,163	Dec 19 05:00 PM
BOUSBIB ARI	See Remarks	Dec 18 '25	Sale	222.43	36,564	8,132,931	820,599	Dec 19 05:00 PM
ARI BOUSBIB	Officer	Dec 18 '25	Proposed Sale	222.43	36,564	8,132,876		Dec 18 05:41 PM
Sherbet Eric	See Remarks	Oct 29 '25	Option Exercise	131.82	10,000	1,318,200	31,108	Oct 31 05:01 PM
Sherbet Eric	See Remarks	Oct 29 '25	Sale	219.70	4,000	878,800	27,108	Oct 31 05:01 PM
BOUSBIB ARI	See Remarks	Oct 29 '25	Option Exercise	59.90	77,592	4,647,761	884,755	Oct 31 05:00 PM
BOUSBIB ARI	See Remarks	Oct 29 '25	Sale	220.33	56,557	12,461,119	828,198	Oct 31 05:00 PM
ARI BOUSBIB	Officer	Oct 29 '25	Proposed Sale	220.33	56,557	12,460,983		Oct 29 04:18 PM
ERIC SHERBET	Officer	Oct 29 '25	Proposed Sale	219.70	4,000	878,820		Oct 29 04:10 PM

NTLA

Intellia Therapeutics Inc

IQV

IQVIA Holdings Inc

Upgrade your Finviz experience